Investor Visit

Smith & Nephew Plc 07 September 2005 Investor visit to Smith & Nephew Orthopaedics 7 September 2005 Smith & Nephew plc, (LSE: SN, NYSE: SNN), the global medical technology business, will be holding a visit for institutional investors and analysts at the global headquarters of the company's orthopaedics business in Memphis, Tennessee, on Thursday 15 September 2005. The visit will be hosted by Chief Executive, Sir Christopher O'Donnell, and Dave Illingworth, President of Smith & Nephew Orthopaedics. During the visit guests will have the opportunity to meet senior management, visit the manufacturing facilities and receive presentations from the heads of Orthopaedics' three businesses, Reconstructive Implants, Trauma and Clinical Therapies. Commenting on the visit, Sir Christopher O'Donnell said 'Smith & Nephew Orthopaedics has consistently been the fastest growing orthopaedics business in the world over the last few years and it will be a pleasure to show our guests some of the exciting new developments which are fuelling our success.' The main presentations of the event will be webcast live on Smith & Nephew's corporate website at www.smith-nephew.com and will begin at 12 noon BST/7am EST on Thursday 15 September 2005. An archive of these presentations will be available on the site shortly after the close. Enquiries Liz Hewitt Tel: +44 (0) 20 7401 7646 Group Director Corporate Affairs About us Smith & Nephew is a global medical technology business, specialising in Orthopaedics, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the fastest growing global orthopaedics companies. Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has over 8,500 employees and operates in 33 countries around the world generating annual sales of £1.25 billion. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and operating margins discussed under 'Outlook' are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors. All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings